Active Clinical Trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.

Showing 190 results
  • Sort by
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location

Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

 		Lymphatic Malformations Phase 2, Phase 3 United States
Australia
France
Germany
Spain
View All

Asciminib RMP Study

 		Chronic Myeloid Leukemia Korea, Republic of

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

 		Oligometastatic Prostate Cancer (OMPC) Phase 3 Australia
Switzerland
Israel
Canada
Singapore
View All

Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

 		Atypical Hemolytic Uremic Syndrome Phase 3 Turkey
Japan

Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa.

 		Hidradenitis Suppurativa Germany

An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

 		Hyperlipoproteinemia (a) Phase 3 Germany

A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma

 		Follicular Lymphoma (FL) Phase 3 Spain
Slovakia
Romania
Hungary
Australia
Poland
Korea, Republic of
Singapore
Taiwan
View All

A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies

 		Primary Immune Thrombocytopenia (ITP) Phase 2 United States
Turkey
Spain
China
Czech Republic
Argentina
Australia
France
Germany
Italy
United Kingdom
Malaysia
Poland
Korea, Republic of
View All

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

 		Breast Cancer Phase 1 Spain
France
Portugal

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

 		Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors United States